So far, so good” was at least one reaction – though not the market’s – to phase I data uncorked by Macrogenics Inc. at the European Society for Medical Oncology meeting in Madrid, where attendees ...

Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology ...

Researchers at ETH Zürich have developed an implant that catalyzed the oxidation of glucose to gluconate, a metabolite that is easily excreted by the kidneys. In mice, the device could rapidly bring ...

The 2026 European Society of Medical Oncology (ESMO) 2026 annual meeting kicked off with a bit of drama, as Merck & Co. Inc. and Moderna Inc. released the full data from their Interpath-001 study two ...

Worldwide biopharma approvals reached 57 in September, up 50% from August’s 38 and coming in as the second-highest monthly total of the year, behind June’s 64. Through the first three quarters of 2026 ...

Following the close of the sale of its Vega Therapeutics Inc. subsidiary to Incyte Inc. for $1.25 billion up-front in July 2026, Star Therapeutics LLC was left with an astronomical amount of cash for ...

Fractyl Health Inc. is determined to pursue the development of its Revita system despite its battered share price and looming litigation. It is cutting nearly half of its workforce, discontinuing the ...

Lycia Therapeutics Inc. is the latest biopharma to go public this year, pricing an IPO of 17.64 million shares at $18 apiece for gross proceeds of $317.5 million to advance clinical work on its ...

It’s been more than four years since the U.S. FTC, at congressional insistence, opened its investigation into pharmacy benefit manager (PBM) practices. The agency needs to wrap it up and release a ...

After failing a phase III trial in sepsis-associated kidney injury in 2022, AM-Pharma’s ilofotase alfa has been acquired by Ambrose Healthcare for up to €161 million (US$181 million) and will be taken ...

Researchers from the University of Osaka have found that, long before antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis progresses to overt kidney injury, stressed renal ...

Ryvu Therapeutics SA recently presented data for RVU-602, a proprietary non-TOPO1/non-tubulin antibody-drug conjugate (ADC) ...